Clinical Trials
22 trialsNCT05613088 2026-04-30
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT06449209 2026-04-17
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
BioNTech SE
Phase 2 Active not recruiting
NCT07076095 2025-07-21
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2 Not yet recruiting
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT04768296 2024-09-26
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
Phase 2 Completed
NCT01904253 2024-09-05
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02200757 2024-06-25
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Completed
NCT00065182 2019-06-24
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT01497873 2018-12-27
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
Phase 2 Completed
NCT00061308 2017-06-09
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00043862 2017-05-31
(SCLC)
GlaxoSmithKline
Phase 2 Completed
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT01630018 2016-09-22
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
Chong Kun Dang Pharmaceutical
Phase 2 Completed
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01121406 2015-08-13
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00316186 2015-05-07
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
GlaxoSmithKline
Phase 2 Completed
NCT01500720 2015-04-13
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Sanofi
Phase 2 Completed
NCT00316173 2012-11-27
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00267488 2012-07-11
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00698516 2012-03-27
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00319969 2009-09-30
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
Celgene
Phase 2 Completed